Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects

• Published in: Nanomaterials (Basel, Switzerland) Vol. 12; no. 20; p. 3567
• Main Authors: Aram, Elham, Moeni, Masome, Abedizadeh, Roya, Sabour, Davood, Sadeghi-Abandansari, Hamid, Gardy, Jabbar, Hassanpour, Ali
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2022; MDPI
• Subjects: Algae; Bacteria; Biocompatibility; Cancer; Cancer therapies; Chemical compounds; Chemotherapy; Contrast media; Drug delivery; Drug delivery systems; Drugs; Fabrication; Ferric oxide; Health aspects; Hyperthermia; Iron compounds; Iron oxides; Li, Dong; Magnetic resonance imaging; Magnetism; Malignancy; Nanoparticles; Pharmacology; Precision medicine; Radiation; Reagents; Review; smart magnetic nanoparticles; theranostics; Toxicity; Ultrasonic imaging; Vehicles; United States
• ISSN: 2079-4991; 2079-4991
• DOI: 10.3390/nano12203567

Iron oxide nanoparticle (IONPs) have become a subject of interest in various biomedical fields due to their magnetism and biocompatibility. They can be utilized as heat mediators in magnetic hyperthermia (MHT) or as contrast media in magnetic resonance imaging (MRI), and ultrasound (US). In addition, their high drug-loading capacity enabled them to be therapeutic agent transporters for malignancy treatment. Hence, smartening them allows for an intelligent controlled drug release (CDR) and targeted drug delivery (TDD). Smart magnetic nanoparticles (SMNPs) can overcome the impediments faced by classical chemo-treatment strategies, since they can be navigated and release drug via external or internal stimuli. Recently, they have been synchronized with other modalities, e.g., MRI, MHT, US, and for dual/multimodal theranostic applications in a single platform. Herein, we provide an overview of the attributes of MNPs for cancer theranostic application, fabrication procedures, surface coatings, targeting approaches, and recent advancement of SMNPs. Even though MNPs feature numerous privileges over chemotherapy agents, obstacles remain in clinical usage. This review in particular covers the clinical predicaments faced by SMNPs and future research scopes in the field of SMNPs for cancer theranostics.